MediPal Holdings Corporation (MAHLY)

Market Cap	3.54B
Revenue (ttm)	24.52B
Net Income (ttm)	268.98M
Shares Out	n/a
EPS (ttm)	1.29
PE Ratio	13.14
Forward PE	n/a
Dividend	0.43 (2.61%)
Ex-Dividend Date	Sep 29, 2025

Volume	104
Average Volume	654
Open	16.94
Previous Close	16.48
Day's Range	16.48 - 17.35
52-Week Range	14.03 - 19.07
Beta	n/a
RSI	55.71
Earnings Date	Aug 5, 2025

About Revance Therapeutics

Medipal Holdings Corporation engages in the prescription pharmaceutical wholesale business in Japan. It procures healthcare products related to diagnostics, testing, treatment, and administration comprises medical equipment and medical materials, and clinical diagnostic reagents for use from the pre-symptomatic stage; handles PMS services on contract for manufacturers; and invests in orphan drugs and other products. The company is involved in the wholesale of cosmetics, daily necessities, and OTC pharmaceuticals; and animal health products for...

• Industry: Medical Distribution
• Sector: Healthcare
• Founded: 1898
• Employees: 13,061
• Stock Exchange: OTCMKTS
• Ticker Symbol: MAHLY

Financial Performance

In 2024, MediPal Holdings's revenue was 3.67 trillion, an increase of 3.16% compared to the previous year's 3.56 trillion. Earnings were 40.28 billion, a decrease of -2.88%.